Menu
Oslo, Norway, 16 December 2024: Reference is made to stock exchange announcements by Thor Medical ASA (the "Company") on 12 December 2024 regarding the completion of a Company private placement and a retail offering. Completion of tranche 2 of the private placement and a potential subsequent offering is conditional on approval by the general meeting of the Company, as described in the stock exchange announcement on 12 December 2024.
The Company hereby calls for an extraordinary general meeting in the Company to be held on 6 January 2025 at 14:00 hours CET at Advokatfirmaet Selmer AS, Ruseløkkveien 14, 0251 Oslo. The full notice is attached. The notice and the documents to which it refers to are available on https://www.thormedical.no/.
DISCLOSURE REGULATION
This information is required to be disclosed under Section 5-12 of the Securities Trading Act.
CONTACTS
Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440, brede.ellingseter@thormedical.no
ABOUT THOR MEDICAL ASA
Thor Medical is an emerging supplier of alpha emitters enabling next generation cancer treatments. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.
